The Myeloproliferative Neoplasms Channel on VJHemOnc is an independent medical education platform, supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2025 | The novel TMPRSS6 antisense inhibitor sapablursen in polycythemia vera: results of IMPRSSION trial
In this video, Ruben Mesa, MD, Levine Cancer Institute, Atrium Health Wake Forest Baptist Comprehensive Cancer Center, Winston Salem, NC, discusses the results of the IMPRSSION clinical trial (NCT05143957), which evaluated the novel TMPRSS6 antisense inhibitor sapablursen for the treatment of polycythemia vera (PV). This interview took place at the 67th ASH Annual Meeting and Exposition, held in Orlando, FL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
Very excited to be the senior author and co-lead of the IMPRSSION study, which was the phase two study of the TMPRSS6 hepcidin mimetic agent of sapablursin. Presented today by my wonderful colleague, Dr Jeanne Palmer. This agent was for patients with PV who are requiring phlebotomies and on either stable doses of a cytoreductive agent or off cytoreductive agent, really trying to decrease the number of phlebotomies and then also measure impact in terms of symptoms and tolerability...
Very excited to be the senior author and co-lead of the IMPRSSION study, which was the phase two study of the TMPRSS6 hepcidin mimetic agent of sapablursin. Presented today by my wonderful colleague, Dr Jeanne Palmer. This agent was for patients with PV who are requiring phlebotomies and on either stable doses of a cytoreductive agent or off cytoreductive agent, really trying to decrease the number of phlebotomies and then also measure impact in terms of symptoms and tolerability. And what Dr Palmer presented was really very positive results from that study to date, both in terms of the ability to decrease the number of phlebotomies that patients need and becoming phlebotomy independent, as well as improvement in symptoms. Part of that is less iron deficiency that the patients have because they’re not requiring phlebotomies, part perhaps by mechanistic action of the medicine themselves, and it overall was a well-tolerated agent. So again, a very important addition to this kind of growing pantheon of hepcidin mimetics that may have important disease therapy implications for patients with polycythemia vera.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
